Area of research
Pulmonary and Respiratory Medicine · Molecular Biology
Research interest
Research interests include Lung Cancer Treatments and Mutations, Melanoma and MAPK Pathways, Cancer Immunotherapy and Biomarkers, and Synthesis and biological activity.
First-line integration of Local Ablative Therapy (LAT) with EGFR Tyrosine Kinase Inhibitors (TKIs) in advanced EGFR+ NSCLC: A Systematic Review and Meta-Analysis
Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry
Induction chemotherapy backbone in frail patients with advanced NSCLC treated with chemotherapy plus pembrolizumab: a single institution retrospective audit of dose intensities from modified regimens.
Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Therapeutic Advances and Biomarkers
SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registry
Emerging drivers in non-small cell lung cancer, is there a role for immunotherapy?—a narrative review
Ineffective target therapy in non-small cell lung cancer harboring BRAF G466R mutation: a case report and biological rationale
Uncommon EGFR mutations in non-small-cell lung cancer
Efficacy of pembrolizumab in lung adenocarcinoma harboring non-V600E BRAF mutation: a case report